Treatment response to ibrutinib
| Best response to IBR . | Whole population . | High-risk features . | sMIPI score . | Treatment . | ||||
|---|---|---|---|---|---|---|---|---|
| ≥1 . | 0 . | 0-3 . | 4-5 . | ≥6 . | IBR + R . | IBR alone . | ||
| PD | 23 of 104 (22.1%) | 14 of 39 (35.9%) | 10 of 66 (15.2%) | 2 of 10 (20.0%) | 7 of 42 (16.7%) | 14 of 51 (27.5%) | 7 of 47 (14.9%) | 16 of 57 (28.1%) |
| SD | 7 of 104 (6.7%) | 2 of 39 (5.1%) | 5 of 66 (7.6%) | 1 of 10 (10.0%) | 3 of 42 (7.1%) | 3 of 51 (5.9%) | 3 of 47 (6.4%) | 4 of 57 (7.0%) |
| PR | 53 of 104 (51.0%) | 15 of 39 (38.5%) | 38/66 (57.6%) | 6 of 10 (60.0%) | 24 of 42 (57.1%) | 22 of 51 (43.1%) | 24 of 47 (51.1%) | 29 of 57 (50.9%) |
| CR | 21 of 104 (20.2%) | 8 of 39 (20.5%) | 13/66 (19.7%) | 1 of 10 (10.0%) | 8 of 42 (19.0%) | 12 of 51 (23.5%) | 13 of 47 (27.7%) | 8 of 57 (14.0%) |
| ORR | 71.2% | 59.0% | 77.3% | 70.0% | 76.2% | 66.7% | 78.7% | 64.9% |
| Best response to IBR . | Whole population . | High-risk features . | sMIPI score . | Treatment . | ||||
|---|---|---|---|---|---|---|---|---|
| ≥1 . | 0 . | 0-3 . | 4-5 . | ≥6 . | IBR + R . | IBR alone . | ||
| PD | 23 of 104 (22.1%) | 14 of 39 (35.9%) | 10 of 66 (15.2%) | 2 of 10 (20.0%) | 7 of 42 (16.7%) | 14 of 51 (27.5%) | 7 of 47 (14.9%) | 16 of 57 (28.1%) |
| SD | 7 of 104 (6.7%) | 2 of 39 (5.1%) | 5 of 66 (7.6%) | 1 of 10 (10.0%) | 3 of 42 (7.1%) | 3 of 51 (5.9%) | 3 of 47 (6.4%) | 4 of 57 (7.0%) |
| PR | 53 of 104 (51.0%) | 15 of 39 (38.5%) | 38/66 (57.6%) | 6 of 10 (60.0%) | 24 of 42 (57.1%) | 22 of 51 (43.1%) | 24 of 47 (51.1%) | 29 of 57 (50.9%) |
| CR | 21 of 104 (20.2%) | 8 of 39 (20.5%) | 13/66 (19.7%) | 1 of 10 (10.0%) | 8 of 42 (19.0%) | 12 of 51 (23.5%) | 13 of 47 (27.7%) | 8 of 57 (14.0%) |
| ORR | 71.2% | 59.0% | 77.3% | 70.0% | 76.2% | 66.7% | 78.7% | 64.9% |
IBR, ibrutinib; PD, progressive disease; PR, partial response; R, rituximab; SD, stable disease.